Clinical research on the improving effect of the glucose metabolism and vascular endothelial function by piceatannol
Not Applicable
- Conditions
- Healthy subject and healthy subject with obesity
- Registration Number
- JPRN-UMIN000018397
- Lead Sponsor
- Kanazawa Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Women who are pregnant, or possibility of pregnant, or wish to pregnant, or lactating. (2)Individual who has a smoking habit. (3)Individual who has a history of allergy to piceatannol (4)Individual who has a food allergy. (5)Participants who are considered unsuitable for inclusion by the attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method * Glucose metabolism: blood glucose, insulin, HbA1c, glycated-albumin * Endothelial function: FMD, ADMA, high sensitivity-CRP
- Secondary Outcome Measures
Name Time Method * Body weight, BMI, amount of body fat, % of body fat, skeletal muscle mass, visceral fat area, (In body) * Changing of the expression and activity of SIRT1 and AMPK on isolated peripheral blood mononuclear cells * Lipid metabolism: TC, HDL-C, TG, LDL-C, FFA * Inflammation: IL-6 * Fatigue: d-ROM, BAP, VAS test (Japan Society of fatigue Science, supervision) * Metabolites of piceatannol in blood and urine * Urinary albumin and creatinine * POMS(Mood profile test, questionnaire method) * Safety of throughout the entire study period